Analyst consensus rating
MoonLake Immunotherapeutics Analyst Rating: Buy
Direct answer
MoonLake Immunotherapeutics's consensus rating is Buy.
13 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $28.54.
Forecast evidence checked October 19, 2026.
Get free MoonLake Immunotherapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $9.55
- Average price target
- $28.54
- High price target
- $50.00
- Low price target
- $6.00
- Low target gap
- -37.2%
- Target upside
- +198.8%
- High target gap
- +423.6%
- Target range width
- 460.7%
- Consensus rating
- Buy
- Analysts
- 13
- Evidence date
- October 19, 2026
- Valid through
- October 26, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for MoonLake Immunotherapeutics?
MoonLake Immunotherapeutics has a verified Buy consensus. The same dataset has an average price target of $28.54.
How far are MoonLake Immunotherapeutics's low and high targets from the recorded price?
The low target implies -37.2%, while the high target implies +423.6%.
How many analysts are included in MoonLake Immunotherapeutics's consensus?
The verified consensus includes 13 analysts.
How is MoonLake Immunotherapeutics's target upside or downside calculated?
The average target of $28.54 is divided by the recorded price of $9.55, then one is subtracted to produce +198.8%. This does not guarantee a future return.
When was MoonLake Immunotherapeutics's analyst forecast verified?
The data was verified on 2026-10-19. The dataset is valid through 2026-10-26.